Tony and Skeeter,
>> Just good news never seems to help. What is needed is unexpected good news. <<
ISIP's recent good news seems to be helping its share price, despite this bear(?) market.ÿ(What say you all? Have you been looking at this? to see how ISIP trades since its news ???)
ÿ
I was afraid ISIP's first anti-sense NDA would get lost in the market fog, but ISIP's price seems to be recovering lately (got almost to 10.5 today on low volume...) There was excitement just before ISIP's NDA, but I think approval was expected ...
So now I have half a hair of hope that Ligand's Ontak NDA might help it's price (if the related financial issues don't cancel out the pop.)
AT least, the cloud of uncertainty regarding Ligand's ability to get its very first approval should lift -- which might qualify as "unexpected good news."
Regards, Cheryl
-------------------------------------
PS - I just hope Ligand doesn't overpay those exuberant, straining-at-the-leash Ontak salesmen. This is a whole new ballgame coming, as Ligand tries to transition from pure R&D to some production and sales. Startup sales expenses can be amazingly high, and development of successful sales networks can be painfully slow. This has been a dicey time for lots of young, exciting biotechs and med-product firms.
I have in mind our own wonderful local company Heartstream (HTST), which recently
-- at the moment of impending certain profitabity
-- when my due diligence told me the time was finally right for my first purchase of HTST
-- was snatched away by Hewlett Packard, at a per share price less than the IPO price. |
